WASHINGTON — In a milestone achievement against one of the deadliest forms of cancer, the U.S. Food and Drug Administration (FDA) has approved a groundbreaking targeted therapy for patients with advanced pancreatic cancer.
The agency granted expedited approval on Wednesday to Rasonque (generic name daraxonrasib), an oral daily medication that directly tackles a genetic mutation responsible for driving tumor growth in over 90 percent of pancreatic cancer cases. Developed by Redwood City, California-based drugmaker Revolution Medicines, the approval arrived more than six months ahead of the FDA's original target date.
"It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible," said acting FDA Commissioner Kyle Diamantas in an official statement.
Breaking the "Undruggable" Barrier
Pancreatic cancer has long been notoriously difficult to treat. Because early symptoms are rare, most cases are diagnosed only after the disease has metastasized to other organs. Furthermore, the tumor's primary driver—mutations in the RAS gene family, particularly KRAS—possesses a smooth molecular structure that previously prevented therapeutic compounds from binding to it. For decades, researchers considered the protein virtually "undruggable."
Rasonque breaks through this hurdle by acting as a "molecular glue," binding across multiple KRAS subtypes to stop mutant proteins from signaling continuous tumor growth.
Dramatic Survival Improvements
Approval of the drug was backed by a clinical trial involving 500 patients whose late-stage, metastatic pancreatic cancer had ceased responding to standard treatments.
Trial participants receiving Rasonque demonstrated a median overall survival of 13.2 months, compared to 6.7 months for patients given standard chemotherapy—nearly doubling their life expectancy. Patients taking Rasonque also experienced fewer severe side effects, with common adverse reactions limited primarily to skin rashes, mouth sores, diarrhea, and other mild-to-moderate digestive issues.
"This is one of the most anticipated approvals I can think of," said Dr. Andrew Coveler of the Fred Hutch Cancer Center. "This medicine is not a cure, but it represents a significant, meaningful improvement."
Public Interest and Future Implications
Anticipation around daraxonrasib began building earlier this year when high-profile figures, including former U.S. Senator Ben Sasse (R-Neb.), publicly shared their experience with the trial drug, noting marked relief in pain symptoms. Strong public demand prompted the FDA to grant expanded compassionate access to eligible patients prior to full clearance.
Revolution Medicines announced that Rasonque will carry a list price of approximately $39,800 for a one-month supply. The company is currently testing its underlying molecular technology on other hard-to-treat conditions, including KRAS-driven lung cancers.
Oncologists believe Rasonque's clearance could serve as a catalyst for a new generation of targeted therapies across various cancer types.
"I think this has opened doors for many other drugmakers," noted Dr. Pashtoon Kasi, an oncologist at City of Hope Orange County in California. "Downstream, we are going to see many more trials exploring this approach in other complex tumor types."
